Pharmaceutical or dietetic composition having a high antithrombotic and antiarteriosclerotic activity

Abstract: A pharmaceutical or dietetic composition for the preven­ tion and treatment of vascular, arteriosclerotic and thrombo­ tic pathologies, comprised of lecithin and oils having a high content of eicosapentaenoic (C 20:5, n-3) and/or docosahex­ aenoic (C 22:6, n-3) acids, and/or esters thereof. Said composition affords a considerable enhancement of vascular pathologies therapy by the use of natural ingredients commonly employed in human nourishment without any trouble.

Description: This invention concerns a pharmaceutical of dietetic composition having a high antithrombotic and antiarteriosclerotic activity, especially suited for the prevention and/or treatment of vascular diseases in general. It is known that lecithins of natural or synthetic origin, as well as lecithins fractions that are purified or enriched in some of their constituents, show favourable metabolic effects in the prevention and therapy of several pathologies, among which are thrombosis, arteriosclerosis and hyperlimiae. Natural lecithins consist of a mixture of different species of phospholipids whose main constituents are phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol. Such lecithins can be obtained from eggs, tissues from animal organs, and from soybean, turnip and sunflower seeds. Alternatively, said phospholipids can be obtained by chemical synthesis, although high costs discourage adopting this route. DE―A―3,230,103 discloses a composition for oral use, consisting of lecithin and free fatty acids or a vegetable oil in which a particular ratio between phospholipid and oil or free fatty acid is obtained. The listed vegetable oils do not contain eicosapentenoic or docosahexaenoic acids. GB―A―2,080,234 describes a composition containing lecithin and' a minimum quantity of soya oil by which the solubility of lecithin is enhanced. Soya oil does not contain eicosapentenoic or docosahexaenoic acids. DE―A―2,556,592 discloses addition salts of lecithin with alkali metal salts of gallic acids, which are highly soluble infats. Finding a way to overcome said dietetic and pharmacological activity limitations, substantially increasing the antithrombotic and antiarteriosclerotic power of said lecithins is the object of this invention. Attainment of this object is very important considering that lecithins are a natural product and they have passed all acceptability tests due to their age-old presence in man's nourishment. This and other objects for the prevention and treatment of vascular, arteriosclerotic and thrombotic pathologies, are attained by the use of lecithins and of at least one oil extracted from marine animals containing eicosapentenoic acid (C 20:5, n-3) and/or docosahexaenoic acid (C 22:6, n-3) and/or esters thereof for the preparation of compositions for therapeutic or dietetic use having blood platelet anti-aggregating activity, the amount of lecithins with respect to the said at least one oil being 14 to 35 g of lecithins for 100 g of oil. The inventive composition has surprisingly shown a considerable increase of the antithrombotic and antiarteriosclerotic activity of lecithins. Oils obtained from marine animals "in toto" or from organs of same (e.g. cod liver oil) are examples of easily available oils, suited to the purpose of this invention. Such oils are characterized by a high eicosapentaenoic (C 20:5, n-3) and docosahexaenoic (C 22:6, n-3) acids content, such acids being hereinafter referred to as n-3 polyenoic acids, usually present in the form of esters in the triglycerides of said oils. Lecithins (or purified fractions thereof) of natural (soybean, peanut, eggs, animal tissues) and/or synthetic origin are easily available and can be used for the purpose of this invention. According to a preferred embodiment of the invention, the lecithins employed have a high phosphatidyl choline content (phosphatidyl choline should preferably be higher than 20% molar of the phospholipidic content of employed lecithins). Preparation of pharamaceutical or dietetic lecithin-containing compositions for oral use, carried (i.e. vehicled) by oil of high 3-polyenoic acids content, does not require any special attention, thanks to high lecithin solubility in oily carriers. The only restriction is to be found in the fact that double bonds in the acyl chains of lecithins phospholipids and fatty acis of oil triglycerides could undergo peroxidation reactions during mixing operations. This can be obviated by the addition of one or more antioxidant agents when mixing lecithins in oil. As an antioxidant, any of the antioxidants commonly adopted in the food industry can be used: α-tocopherol, ascorbic acid, carotenoids, and derivatives thereof. As an indication, but not as a limitation, a preparation of lecithins in oils of high n-3 polyenoic acids content can be obtained according bo the methods of following Example 1 Example 1 Lecithins (e.g. 21 g soybean lecithin) are dissolved with stirring in 100 ml of an oil of high n-3 polyenoic acids content (e.g. cod liver oil) together with an antioxidant compound (e.g. 1 m mole of α-tocopherol); the solution is stirred for a few minutes, until homogeneous. The above solution can be administered as it is through usual per os pharmaceutical preparations (capsules, gels, tablets, syrups, etc.). The ratio of carried lecithins to oil of high n-3 polyenoic acids content can vary between 1 and 100 g. of lecithin per 100 g. of oil, although a preferable ratio is often of 14―35 g. of lecithin per 100 g. of oily solvent. Pharmacological and dietetic properties As mentioned above, lecithins possess therapeutical properties in the prevention and treatment of several pathologies, among which thrombosis, arteriosclerosis and hyperlimiae. As exposed more detailed in the following Examples; co-carrying lecithins in oils of high n-3 polyenoic acids conent is an essential factor to enhance the properties of the active principles contained in the formulations and to prevent and to decrease platelet aggregation, thus contributing to prevent those metabolic damages that give rise to vascular and arteriosclerotic pathologies. The pharmacological preparation properties are evidenced by the following experiments that prove: effect of the preparation on ADP-induced platelet aggregation, effect of the preparation on collagen-induced platelet aggregation, effect of the preparation on thrombin-induced platelet aggregation. Example 2 Effect of soybean lecithins co-carried in cod liver oil upon ADP-induced platelet aggregation Three New Zealand strain rabbits (average initial weight 1.41±0.03 Kg.) were held for 15 days in single cages with food and water ad libitum. The three animals underwent no pharmaceutical or dietetic treatment and were used as a control group. At the end of the experiment, an aliquot of blood was drawn from the ear central artery and collected in a 3.8% sodium-citrate buffer (pH 7.4). Plasma platelet fractions were obtained employing standard methods (centrifugation). Platelet aggregation induced by increasing ADP dosages (5―40 µm) was measured in each sample with an aggregometer. The obtained results are shown in Fig. 1, wherein ordinates represent percentages of light conveyed to the aggregometer, and abscissae represent final ADP concentrations. Example 2 results are represented in Fig. 1 by the empty-ring-marked broken line. Example 3 Example 2 is repeated except that animals are administered with a daily dosage of the invention composition containing 500 mg of soybean lecithin and 2 g. of cod liver oil, for 15 consecutive days. Example 3 results are represented in Fig. 1 by the empty-squares-marked broken line. Example 4 Example 2 is repeated except that animals are administered with a daily dosage of 500 mg soybean lecithin in water, and 2 hours later, a 2 g. dosage of cod liver oil, for 15 consecutive days. Example 4 results are shown in Fig. 1 by the black-round-spots-marked broken line. It will be obvious, from a comparison of Examples 2, 3 and 4, that only through a simultaneous per os administration of lecithin and an oil having a high content of n-3 polyenoic acids or esters thereof can a high inhibition of ADP-induced platelet aggregation be obtained. The same dosage of lecithin and cod liver oil, separately administered at 2-hours' time interval, show littel effect, just irrelevantly different from the Example 2 (control) values. Example 5 Effect of soybean lecithin co-carried in cod liver oil upon collagen-induced platelet aggregation Animals were treated as in Example 2, except that platelet aggregation was induced here by collagen dissolved in acetic acid and added to the platelet medium in amounts varying from 2.5 to 20 µg, instead of ADP. Example 5 results are shown in Fig. 2, wherein ordinates represent the light percentage conveyed and abscissae represent final collagen concentration by the empty-ring-marked broken line. Example 6 Example 5 is repeated, except that animals were administered a daily dosage of a composition according to the invention, containing 500 mg of soybean lecithin and 2 g. cod liver oil, for 15 consecutive days. Example 6 results are represented in Fig. 2 by the empty-squares-marked broken line. Example 7 Example 5 is repeated, except that animals were administered a daily dosage of 500 mg soybean lecithin in water and, two hours later, a 2 g. dosage of cod liver oil, for 15 consecutive days. Example 7 results are represented in Fig. 2 by the black-spots-marked broken line. Through a comparison of Examples 5, 6 and 7, it clearly appears that only a per os simultaneous administration of lecithin in combination with a oil having a high content of n-3 polyenoic acids or esters thereof can give rise to a high inhibition of collagen-induced platelet aggregation. Example 8 Effect of soybean lecithins co-carried in cod liver oil upon thrombin-induced platelet aggregation Example 2 was repeated except that platelet aggregation was not induced by ADP, but was induced by bovine thrombin added to the platelet medium in amounts varying from 0.5 to 2.5 U. Results are shown in Fig. 3, wherein ordinates represent light percentage conveyed to the aggregometer and abscissae represent thrombin concentration. Example 8 results are represented in Fig. 3 by the empty-ring-marked broken line. Example 9 Example 8 is repeated, except that animals are administered with a daily dosage of a composition according to the invention, containing 500 mg lecithin and 2 g cod liver oil, for 15 consecutive days. Example 9 results are represented in Fig. 3 by the empty-squares-marked broken line. Example 10 Example 8 was repeated, except that animals were administered with a daily dosage of 500 mg. soybean lecithin in water and, two hours later, a 2 g. dosage of cod liver oil for 15 consecutive days. Example 10 results are represented in Fig. 3 by the black-round-spot-marked broken line. A comparison of Examples 8, 9 and 10, wherein thrombin is used, leads to the same results of previous Examples: only through a simultaneous administration of the ingredients according to this invention can a substantial inhibition of platelet aggregation be obtained. Cod liver oil employed in Examples 1, 3, 4, 6, 7, 9 and 10 have the following weight compositions: C 12:0 Trace C 14:0 5.95 C 16:0 18.89 C 16:1 7.83 C 18:0 3.53 C 18:1 17.41 C 18:2, n-6 12.33 C 18:3, n-3 3.52 C 20:4, n-6 0.58 C 20:5, n-3 9.87 C 22:5, n-3 1.04 C 22:6, n-3 5.50

Claims: Use of lecithins and of at least one oil extracted from marine animals containing eicosapentenoic acid (C 20:5, n-3) and/or docosahexaenoic acid (C 22:6, n-3) and/or esters thereof for the preparation of compositions for therapeutic or dietetic use having blood platelet anti-aggregating activity, the amount of lecithins with respect to the said at least one oil being 14 to 35 g of lecithins for 100 g of oil. Use according to claim 1, characterized in that said amount of lecithins is 21 g for 100 g of oil. Use according claim 1, characterized in that said lecithins have a phosphatidylcholine content of not less than 20% molar, based on total phospholipid content. Use according to claim 1, characterized in that it also contains an antioxidant lipid compound. Use according to claim 4, characterized in that said antioxidant lipid compound is selected from tocopherol and derivatives thereof, ascorbic acid and derivatives thereof, and carotenoids and derivatives thereof. Use according to anyone of the preceding claims, characterized in that the ratio of said lecithins to said oils is of 1-99 g of lecithins per 100 g. of oils.

Inventors: PISTOLESI ELVIRA, PISTOLESI, ELVIRA
Applicants: PISTOLESI ELVIRA, PISTOLESI, ELVIRA
Application year: 1985
Main classification: A61K31
IPC codes: A23L1, A61K35, A61P7, A61K38, A61K31, A61K36, A61P9